Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, and The Alpha-1 Project (TAP), the venture philanthropy
subsidiary of the Alpha-1 Foundation, announced today that they have
entered into a collaboration agreement for the continued advancement of
ALN-AAT, a subcutaneously administrated RNAi therapeutic in development
for the treatment of alpha-1 antitrypsin (AAT) deficiency-associated
Sign-up for Alnylam and The Alpha-1 Project (TAP) Form Collaboration for Advancement of ALN-AAT, an RNAi Therapeutic in Development for the Treatment of Alpha-1 Antitrypsin (AAT) Deficiency-Associated Liver Disease investment picks
Sign-up for Alnylam Broadens Pipeline with ALN-AGT, a Subcutaneously Administered RNAi Therapeutic Targeting Angiotensinogen (AGT) for the Treatment of Hypertensive Disorders of Pregnancy (HDP), Including Preeclampsia investment picks
Sign-up for Alnylam Receives Notice of Allowance from United States Patent and Trademark Office (USPTO) for New Patent Broadly Covering RNAi-Mediating Double-Stranded Molecules Comprising Up to 25 Base Pairs investment picks
Pharmaceuticals , Inc. (Nasdaq: ALNY), a
leading RNAi therapeutics company, today announced that it has added
three new events to its series of online “RNAi Roundtables” that it is
hosting during July and August.
Sign-up for Alnylam Receives Notice of Allowance from United States Patent and Trademark Office (USPTO) for New Patent Broadly Covering RNAi-Mediating, Double-Stranded Molecules of 19 to 52 Nucleotides in Length investment picks
The Medicines Company (NASDAQ:MDCO) today announced that in
collaboration with Alnylam Pharmaceuticals (NASDAQ:ALNY) it will be
hosting the “ALN-PCSsc for the treatment of Hypercholesterolemia” RNAi
Roundtable webcast on August 14, 2014.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.